Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Binrui Chen, Shuwen Zhu, Lijun Du, Huiqin He, John J. Kim & Ning Dai. (2017) Reduced interstitial cells of Cajal and increased intraepithelial lymphocytes are associated with development of small intestinal bacterial overgrowth in post-infectious IBS mouse model. Scandinavian Journal of Gastroenterology 52:10, pages 1065-1071.
Read now
Read now
Annalisa Ricci, Erika Coppo, Ramona Barbieri, Eugenio A. Debbia & Anna Marchese. (2017) The effect of sub-inhibitory concentrations of rifaximin on urease production and on other virulence factors expressed by Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. Journal of Chemotherapy 29:2, pages 67-73.
Read now
Read now
Augusto Lauro, Roberto De Giorgio & Antonio Daniele Pinna. (2015) Advancement in the clinical management of intestinal pseudo-obstruction. Expert Review of Gastroenterology & Hepatology 9:2, pages 197-208.
Read now
Read now
Chaitanya Pant, Abhishek Deshpande, Anne Larson, Judith O’Connor, David D.K. Rolston & Thomas J. Sferra. (2013) Diarrhea in solid-organ transplant recipients: a review of the evidence. Current Medical Research and Opinion 29:10, pages 1315-1328.
Read now
Read now
Shamaila Butt & Anton Emmanuel. (2013) Systemic sclerosis and the gut. Expert Review of Gastroenterology & Hepatology 7:4, pages 331-339.
Read now
Read now
Ron Schey & Satish SC Rao. (2011) The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. Expert Review of Gastroenterology & Hepatology 5:4, pages 461-464.
Read now
Read now
Giovanni Latella & Carmelo Scarpignato. (2009) Rifaximin in the management of colonic diverticular disease. Expert Review of Gastroenterology & Hepatology 3:6, pages 585-598.
Read now
Read now
Articles from other publishers (65)
Yorinobu Maeda & Teruo Murakami. (2023) Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth. Antibiotics 12:2, pages 263.
Crossref
Crossref
Shengyan Zhang, Gaichao Hong, Gangping Li, Wei Qian, Yu Jin & Xiaohua Hou. (2023) Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice. BMC Microbiology 23:1.
Crossref
Crossref
K. O. Kuznetsov, A. J. Mikheeva, A. A. Ishmukhametova, T. A. Tolstykh, A. R. Gallyametdinova, Z. U. Botirova, A. A. Zabirova, A. Sh. Sharipova, A. B. Shaikhlislamova & D. R. Abdrakhmanova. (2022) Diabetic gastroenteropathy: modern methods of diagnosis and treatment. Problems of Endocrinology 68:5, pages 67-78.
Crossref
Crossref
Christopher K. Rayner & Michael Horowitz. 2022. Pathy's Principles and Practice of Geriatric Medicine. Pathy's Principles and Practice of Geriatric Medicine
229
246
.
Vikram Mahajan, Suman Singh, Priyanka Thakur, Amisha Kukreja & Rohit Negi. (2022) Severe Sunburn-Like Adverse Cutaneous Drug Reaction in a Patient on Treatment with
Rifaximin: A Rare Case of Acute Phototoxic Drug Reaction. EMJ Dermatology.
Crossref
Crossref
S De Meulder & T Vanuytsel. (2022) Chronic intestinal pseudo-obstruction: a case report with review of the literature and practical guidance for the clinician. Acta Gastro Enterologica Belgica 85:1, pages 85-93.
Crossref
Crossref
Jordi Serra. (2022) Management of bloating. Neurogastroenterology & Motility 34:3.
Crossref
Crossref
Zuojing Liu, Shiwei Zhu, Meibo He, Mo Li, Hui Wei, Lu Zhang, Qinghua Sun, Qiong Jia, Nan Hu, Yuan Fang, Lijin Song, Chen Zhou, Heqing Tao, John Y Kao, Huaiqiu Zhu, Chung Owyang & Liping Duan. (2022) Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity. Chinese Medical Journal 135:14, pages 1716-1727.
Crossref
Crossref
Fenghua Xu, Ning Li, Chun Wang, Hanyang Xing, Dongfeng Chen & Yanling Wei. (2021) Clinical efficacy of fecal microbiota transplantation for patients with small intestinal bacterial overgrowth: a randomized, placebo-controlled clinic study. BMC Gastroenterology 21:1.
Crossref
Crossref
Marcio José Concepción Zavaleta, Jhean Gabriel Gonzáles Yovera, Diego Martín Moreno Marreros, Luciana del Pilar Rafael Robles, Kely Roxana Palomino Taype, Karen Nohelly Soto Gálvez, Luis Fernando Arriola Torres, Julia Cristina Coronado Arroyo & Luis Alberto Concepción Urteaga. (2021) Diabetic gastroenteropathy: An underdiagnosed complication. World Journal of Diabetes 12:6, pages 794-809.
Crossref
Crossref
Andrea Piccioni, Laura Franza, Mattia Brigida, Christian Zanza, Enrico Torelli, Martina Petrucci, Rebecca Nicolò, Marcello Covino, Marcello Candelli, Angela Saviano, Veronica Ojetti & Francesco Franceschi. (2021) Gut Microbiota and Acute Diverticulitis: Role of Probiotics in Management of This Delicate Pathophysiological Balance. Journal of Personalized Medicine 11:4, pages 298.
Crossref
Crossref
Yu Song, Yuan Liu, Baozhen Qi, Xiaotong Cui, Xinyue Dong, Yanyan Wang, Xueting Han, Fuhai Li, Dongli Shen, Xian Zhang, Kai Hu, Shiyao Chen, Jingmin Zhou & Junbo Ge. (2021) Association of Small Intestinal Bacterial Overgrowth With Heart Failure and Its Prediction for Short‐Term Outcomes. Journal of the American Heart Association 10:7.
Crossref
Crossref
Michel Bouchoucha, Marinos Fysekidis, Céline Lekhal, Bakhtiar Daniel Bejou, Jean-Marc Sabate & Robert Benamouzig. (2021) COLIGENTA treatment of small intestinal bacterial overgrowth. Results of an open study.. Digestive and Liver Disease 53:1, pages 66-71.
Crossref
Crossref
Anastasios Tentolouris & Nikolaos Tentolouris. 2021. Autonomic Nervous System and Sleep. Autonomic Nervous System and Sleep
307
315
.
Péter Varjú, Birgit Ystad, Noémi Gede, Péter Hegyi, Dániel Pécsi & József Czimmer. (2020) The role of small intestinal bacterial overgrowth and false positive diagnosis of lactose intolerance in southwest Hungary—A retrospective observational study. PLOS ONE 15:5, pages e0230784.
Crossref
Crossref
Mehran Mesgari-Abbasi, Solin Ghaderi, Monire Khordadmehr, Katayoon Nofouzi, Hossein Tayefi-Nasrabadi & Graham McIntyre. (2019)
Enteroprotective effect of
Tsukamurella inchonensis
on streptozotocin induced type 1 diabetic rats
. Turkish Journal of Biochemistry 44:5, pages 683-691.
Crossref
Crossref
Manuele Furnari, Alessandra De Alessandri, Federico Cresta, Maria Haupt, Marta Bassi, Angela Calvi, Riccardo Haupt, Giorgia Bodini, Iftikhar Ahmed, Francesca Bagnasco, Edoardo Giovanni Giannini & Rosaria Casciaro. (2018) The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. Journal of Gastroenterology 54:3, pages 261-270.
Crossref
Crossref
Behrouz Keleidari, Mohsen Mahmoudieh, Khadije Gorgi, Erfan Sheikhbahaei & Shahab Shahabi. (2019) Hepatic Failure After Bariatric Surgery: A Systematic Review. Hepatitis Monthly In Press:In Press.
Crossref
Crossref
Michele Di Stefano & Eamonn M. M. Quigley. (2018) The diagnosis of small intestinal bacterial overgrowth: Two steps forward, one step backwards?. Neurogastroenterology & Motility 30:11, pages e13494.
Crossref
Crossref
Binrui Chen, John Jae-Woo Kim, Yawen Zhang, Lijun Du & Ning Dai. (2018) Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. Journal of Gastroenterology 53:7, pages 807-818.
Crossref
Crossref
Yoshihide Asano, Masatoshi Jinnin, Yasushi Kawaguchi, Masataka Kuwana, Daisuke Goto, Shinichi Sato, Kazuhiko Takehara, Masaru Hatano, Manabu Fujimoto, Naoki Mugii & Hironobu Ihn. (2018) Diagnostic criteria, severity classification and guidelines of systemic sclerosis. The Journal of Dermatology 45:6, pages 633-691.
Crossref
Crossref
Yang T. Du, Christopher K. Rayner, Karen L. Jones, Nicholas J. Talley & Michael Horowitz. (2018) Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management. Diabetes Care 41:3, pages 627-637.
Crossref
Crossref
Jung Hyun Jo, Soo Jung Park, Jae Hee Cheon, Tae Il Kim & Won Ho Kim. (2018) Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Behçet's disease. Journal of Gastroenterology and Hepatology 33:2, pages 375-379.
Crossref
Crossref
Marinko Marušić, Rosana Troskot Perić & Nikolina Tolj Karaula. 2018. Gastrointestinal Complications of Diabetes. Gastrointestinal Complications of Diabetes
191
201
.
Mislav Jelaković & Silvija Čuković-Čavka. 2018. Gastrointestinal Complications of Diabetes. Gastrointestinal Complications of Diabetes
137
142
.
Jonathan Gotfried, Stephen Priest & Ron Schey. (2017) Diabetes and the Small Intestine. Current Treatment Options in Gastroenterology 15:4, pages 490-507.
Crossref
Crossref
Stanislas A. Doffou, Kissi Henriette Anzouan-Kacou, Eugene K. Messou, Demba A. Bangoura, Dimitri H. Kouamé, Kouame M. Alassan, Constant Assi, Fulgence Mamert Y. Bathaix, Alain K. Attia & Marie-Jeanne K. Lohoues. (2017) Assessment of the Efficacy of Rifaximin in the Management of Irritable Bowel Syndrome (IBS). Open Journal of Gastroenterology 07:10, pages 261-270.
Crossref
Crossref
G. Di Nardo, C. Di Lorenzo, A. Lauro, V. Stanghellini, N. Thapar, T. B. Karunaratne, U. Volta & R. De Giorgio. (2016) Chronic intestinal pseudo‐obstruction in children and adults: diagnosis and therapeutic options. Neurogastroenterology & Motility 29:1.
Crossref
Crossref
Jasmeet S. Mokha & Jeffrey S. Hyams. 2017. Pediatric Neurogastroenterology. Pediatric Neurogastroenterology
399
410
.
David H. Kerman. (2016) Endoscopic Delivery of Fecal Biotherapy in Inflammatory Bowel Disease. Gastrointestinal Endoscopy Clinics of North America 26:4, pages 707-717.
Crossref
Crossref
Abigail Maisey. (2016) A Practical Approach to Gastrointestinal Complications of Diabetes. Diabetes Therapy 7:3, pages 379-386.
Crossref
Crossref
Rafid Kasir, Salam Zakko, Philip Zakko, Michael Adler, Aaron Lee, Sachin Dhingra & Cecile Guttermuth. (2015) Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome. Digestive Diseases and Sciences 61:3, pages 846-851.
Crossref
Crossref
Shino Shimura, Norihisa Ishimura, Hironobu Mikami, Eiko Okimoto, Goichi Uno, Yuji Tamagawa, Masahito Aimi, Naoki Oshima, Shuichi Sato, Shunji Ishihara & Yoshikazu Kinoshita. (2015) Small Intestinal Bacterial Overgrowth in Patients with Refractory Functional Gastrointestinal Disorders. Journal of Neurogastroenterology and Motility 22:1, pages 60-68.
Crossref
Crossref
Maria‐Pia Bernardi, Satish Warrier, A. Craig Lynch & Alexander G. Heriot. (2015) Acute and chronic pseudo‐obstruction: a current update. ANZ Journal of Surgery 85:10, pages 709-714.
Crossref
Crossref
Doron Boltin, Tsachi Tsadok Perets, Einav Shporn, Shoshana Aizic, Sigal Levy, Yaron Niv & Ram Dickman. (2014) Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Annals of Clinical Microbiology and Antimicrobials 13:1.
Crossref
Crossref
Jose L. Barboza, Nicholas J. Talley & Baharak Moshiree. (2014) Current and Emerging Pharmacotherapeutic Options for Irritable Bowel Syndrome. Drugs 74:16, pages 1849-1870.
Crossref
Crossref
Stephen M. Collins. (2014) A role for the gut microbiota in IBS. Nature Reviews Gastroenterology & Hepatology 11:8, pages 497-505.
Crossref
Crossref
Victor Chedid, Sameer Dhalla, John O. Clarke, Bani Chander Roland, Kerry B. Dunbar, Joyce Koh, Edmundo Justino, Eric Tomakin, Rn & Gerard E. Mullin. (2014) Herbal Therapy is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth. Global Advances in Health and Medicine 3:3, pages 16-24.
Crossref
Crossref
Max Schmulson, María Victoria Bielsa, Ramón Carmona-Sánchez, Angélica Hernández, Aurelio López-Colombo, Yolanda López Vidal, Mario Peláez-Luna, José María Remes-Troche, José Luis Tamayo & Miguel Angel Valdovinos. (2014) Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review. Revista de Gastroenterología de México (English Edition) 79:2, pages 96-134.
Crossref
Crossref
M. Schmulson, M.V. Bielsa, R. Carmona-Sánchez, A. Hernández, A. López-Colombo, Y. López Vidal, M. Peláez-Luna, J.M. Remes-Troche, J.L. Tamayo & M.A. Valdovinos. (2014) Microbiota, infecciones gastrointestinales, inflamación de bajo grado y antibioticoterapia en el síndrome de intestino irritable. Una revisión basada en evidencias. Revista de Gastroenterología de México 79:2, pages 96-134.
Crossref
Crossref
Motoyori Kanazawa & Shin Fukudo. (2013) Relationship between infectious gastroenteritis and irritable bowel syndrome. Clinical Journal of Gastroenterology 7:1, pages 14-18.
Crossref
Crossref
Brigid S. Boland, Steven V. Edelman & James D. Wolosin. (2013) Gastrointestinal Complications of Diabetes. Endocrinology and Metabolism Clinics of North America 42:4, pages 809-832.
Crossref
Crossref
Martin Raithel, Michael Weidenhiller, Alexander Fritz-Karl Hagel, Urban Hetterich, Markus Friedrich Neurath & Peter Christopher Konturek. (2013) The Malabsorption of Commonly Occurring Mono and Disaccharides. Deutsches Ärzteblatt international.
Crossref
Crossref
E. Grace, C. Shaw, K. Whelan & H. J. N. Andreyev. (2013) Review article: small intestinal bacterial overgrowth - prevalence, clinical features, current and developing diagnostic tests, and treatment. Alimentary Pharmacology & Therapeutics 38:7, pages 674-688.
Crossref
Crossref
Mi-Sung Kim, Walter Morales, Andres Ardila Hani, Sharon Kim, Gene Kim, Stacy Weitsman, Christopher Chang & Mark Pimentel. (2013) The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance. Digestive Diseases and Sciences 58:6, pages 1676-1682.
Crossref
Crossref
Kim L. Isaacs. (2013) Rifaximin in IBD. Inflammatory Bowel Diseases 19:2, pages 457-458.
Crossref
Crossref
Bella Zeisler & Jeffrey S. Hyams. 2013. Pediatric Neurogastroenterology. Pediatric Neurogastroenterology
367
376
.
Jie Cheng, Kristopher W. Krausz, Naoki Tanaka & Frank, J. Gonzalez. (2012) Chronic Exposure to Rifaximin Causes Hepatic Steatosis in Pregnane X Receptor-Humanized Mice. Toxicological Sciences 129:2, pages 456-468.
Crossref
Crossref
A. Gatopoulou, N. Papanas & E. Maltezos. (2012) Diabetic gastrointestinal autonomic neuropathy: Current status and new achievements for everyday clinical practice. European Journal of Internal Medicine 23:6, pages 499-505.
Crossref
Crossref
József Hamvas. (2012) Proton-pump inhibitor therapy and small bowel bacterial contamination. Orvosi Hetilap 153:33, pages 1287-1293.
Crossref
Crossref
Jie Cheng, Yatrik M. Shah & Frank J. Gonzalez. (2012) Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends in Pharmacological Sciences 33:6, pages 323-330.
Crossref
Crossref
Christopher K. Rayner & Michael Horowitz. 2012. Pathy's Principles and Practice of Geriatric Medicine. Pathy's Principles and Practice of Geriatric Medicine
247
263
.
Stacy B Menees, Monthira Maneerattannaporn, Hyungjin Myra Kim & William D Chey. (2012) The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology 107:1, pages 28-35.
Crossref
Crossref
Roberto De Giorgio, Rosanna F. Cogliandro, Giovanni Barbara, Roberto Corinaldesi & Vincenzo Stanghellini. (2011) Chronic Intestinal Pseudo-Obstruction: Clinical Features, Diagnosis, and Therapy. Gastroenterology Clinics of North America 40:4, pages 787-807.
Crossref
Crossref
Matthew S. Chang, Maria T. Minaya, Jianfeng Cheng, Bradley A. Connor, Suzanne K. Lewis & Peter H. R. Green. (2011) Double-Blind Randomized Controlled Trial of Rifaximin for Persistent Symptoms in Patients with Celiac Disease. Digestive Diseases and Sciences 56:10, pages 2939-2946.
Crossref
Crossref
Beom Jae Lee & Young-Tae Bak. (2011) Irritable Bowel Syndrome, Gut Microbiota and Probiotics. Journal of Neurogastroenterology and Motility 17:3, pages 252-266.
Crossref
Crossref
Orla F. Craig & Eamonn M. M. Quigley. (2010) Current and emerging therapies for the management of functional gastrointestinal disorders. Therapeutic Advances in Chronic Disease 2:2, pages 87-99.
Crossref
Crossref
Emeran A. MayerKirsten Tillisch. (2011) The Brain-Gut Axis in Abdominal Pain Syndromes. Annual Review of Medicine 62:1, pages 381-396.
Crossref
Crossref
Mark Pimentel, Anthony Lembo, William D. Chey, Salam Zakko, Yehuda Ringel, Jing Yu, Shadreck M. Mareya, Audrey L. Shaw, Enoch Bortey & William P. Forbes. (2011) Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. New England Journal of Medicine 364:1, pages 22-32.
Crossref
Crossref
Madhulika G. Varma & Brooke H. Gurland. 2011. The ASCRS Textbook of Colon and Rectal Surgery. The ASCRS Textbook of Colon and Rectal Surgery
535
548
.
Ian M Carroll, Young-Hyo Chang, Jiwon Park, R Balfour Sartor & Yehuda Ringel. (2010) Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathogens 2:1.
Crossref
Crossref
Brennan M R Spiegel. (2010) Treatment Strategies for Acid Reflux: EncomPASSing Practical Solutions for Primary Care. American Journal of Gastroenterology 105:11, pages 2347-2349.
Crossref
Crossref
M. Furnari, A. Parodi, L. Gemignani, E. G. Giannini, S. Marenco, E. Savarino, L. Assandri, V. Fazio, D. Bonfanti, S. Inferrera & V. Savarino. (2010) Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Alimentary Pharmacology & Therapeutics 32:8, pages 1000-1006.
Crossref
Crossref
Peter Layer. 2010. Handbuch Gastroenterologie 2010. Handbuch Gastroenterologie 2010
303
332
.
Judit Bajor & Tamás Beró. (2009) Diarrhea, from the gastroenterologist’s point of view. Orvosi Hetilap 150:35, pages 1655-1661.
Crossref
Crossref